{
    "clinical_study": {
        "@rank": "14786", 
        "arm_group": {
            "arm_group_label": "MOR00208 (formerly Xmab5574)", 
            "arm_group_type": "Experimental", 
            "description": "intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multicentre study to characterize the safety and preliminary efficacy\n      of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory\n      non-Hodgkin\u00b4s lymphoma (NHL) who have received at least 1 prior therapy containing rituximab\n      (at least once)."
        }, 
        "brief_title": "Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin\u00b4s Lymphoma (NHL)", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. male or female patients \u2265 18 years of age.\n\n          2. histologically-confirmed diagnosis according to REAL/WHO classification, of the\n             following B-cell lymphomas :\n\n               1. FL\n\n               2. MCL\n\n               3. DLBCL\n\n               4. Other indolent NHL (eg, MZL/MALT)\n\n          3. Patients' NHL must have progressed after at least 1 prior rituximab containing\n             regimen.\n\n          4. one site of measurable disease by magnetic resonance imaging (MRI) or computed\n             tomography (CT) scan defined as at least one lesion that measures at least 1.5 \u00d7 1.5\n             cm,\n\n             Exception:\n\n             For patients with MCL only, patients with nonmeasurable disease but evaluable sites\n             (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.\n\n          5. Patients who have previously received an autologous stem cell transplantation must be\n             at least 4 weeks post-transplant before study drug administration and must have\n             exhibited a full haematological recovery\n\n          6. discontinued previous monoclonal antibody therapy (except rituximab) or\n             radioimmunotherapy administration for at least 60 days before study drug\n             administration.\n\n          7. off rituximab for at least 14 days before the screening visit and be confirmed to\n             have either no response or have disease progression after rituximab treatment.\n\n          8. Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission\n             tomography (FDG-PET) scan at baseline (Cheson response criteria)\n\n          9. Life expectancy of > 3 months.\n\n         10. ECOG performance status of < 3.\n\n         11. laboratory criteria at screening:\n\n               1. Absolute neutrophil count (ANC) \u2265 1.0 (1000/mm3)\n\n               2. Platelet count \u2265 75 \u00d7 109/L without previous transfusion within 10 days of first\n                  study drug administration\n\n               3. Haemoglobin \u2265 8.0 g/dL (may have been transfused)\n\n               4. Serum creatinine < 2.0 x upper limit of normal (ULN)\n\n               5. Total bilirubin \u2264 2.0 \u00d7 ULN\n\n               6. Alanine transaminase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 \u00d7 ULN.\n\n         12. If a female of childbearing potential, a negative pregnancy test must be confirmed\n             before enrolment and use of double-barrier contraception, oral contraceptive plus\n             barrier contraceptive, or confirmation of having undergone clinically documented\n             total hysterectomy and/or oophorectomy, tubal ligation.\n\n         13. If a male, an effective barrier method of contraception must be used during the study\n             and for 3 months after the last dose if the patient is sexually active with a female\n             of childbearing potential.\n\n         14. able to comply with all study-related procedures, medication use, and evaluations.\n\n         15. able understand and give written informed consent and comply with the study protocol.\n\n        Exclusion Criteria:\n\n          1. Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other\n             lymphoma specific therapy within 14 days before the screening visit or patient has\n             not recovered from side effects of previous lymphoma-specific therapy.\n\n          2. Treatment with a systemic investigational agent within 28 days before the screening\n             visit.\n\n          3. Previous treatment with an anti-CD19 antibody or fragments\n\n          4. Previous allogenic stem cell transplantation.\n\n          5. Known or suspected hypersensitivity to the excipients contained in the study drug\n             formulation.\n\n          6. Clinically significant cardiovascular disease or cardiac\n             insufficiency,cardiomyopathy, preexisting clinically significant arrhythmia, acute\n             myocardial infarction within 3 months of enrolment, angina pectoris within 3 months\n             of enrolment.\n\n          7. Clinical or laboratory evidence of active hepatitis B or hepatitis C 8. History of\n             HIV infection.\n\n        9. Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral\n        antibiotic therapy within 4 weeks of study drug administration.\n\n        10. Current treatment with immunosuppressive agents other than prescribed corticosteroids\n        (not more than 10-mg prednisone equivalent).\n\n        11. Major surgery or radiation therapy within 4 weeks before first study drug\n        administration.\n\n        12. Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study\n        treatment in the investigator's opinion.\n\n        13. History or clinical evidence of central nervous system (CNS), meningeal, or epidural\n        disease, including brain metastasis.\n\n        14. Active treatment/chemotherapy for another primary malignancy within the past 5 years\n        15. Pregnancy or breastfeeding in women and women of childbearing potential not using an\n        acceptable method of birth control.\n\n        16. History of noncompliance to medical regimens or patients who are considered\n        potentially unreliable not cooperative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685008", 
            "org_study_id": "MOR208C201", 
            "secondary_id": "2012-002659-41"
        }, 
        "intervention": {
            "arm_group_label": "MOR00208 (formerly Xmab5574)", 
            "intervention_name": "MOR00208 (formerly Xmab 5574)", 
            "intervention_type": "Drug", 
            "other_name": "MOR208"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "NHL", 
            "CD19", 
            "MOR208", 
            "MOR00208", 
            "Xmab5574", 
            "B-Cell Non-Hodgkin\u00b4s Lymphoma", 
            "Fc-optimized Anti-CD19 Antibody"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jennifer.long@norwalkhealth.org", 
                    "last_name": "Jennifer Long", 
                    "phone": "203-852-2996"
                }, 
                "facility": {
                    "address": {
                        "city": "Norwalk", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06856"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "investigator": {
                    "last_name": "Richard Frank, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "agoy@humed.com", 
                    "last_name": "Andre Goy, MD", 
                    "phone": "201-336-8772"
                }, 
                "contact_backup": {
                    "email": "kyannotti@hackensackumc.org", 
                    "last_name": "Kara Yannotti", 
                    "phone": "201-495-0605"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "investigator": {
                    "last_name": "Andre Goy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43201"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Donald Quick, MD", 
                    "phone": "806-725-8000"
                }, 
                "contact_backup": {
                    "email": "cottone1@covhs.org", 
                    "last_name": "Erin Cotton", 
                    "phone": "806.725.8001"
                }, 
                "facility": {
                    "address": {
                        "city": "Lubbock", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "79410"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "investigator": {
                    "last_name": "Donald Quick, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels #1", 
                        "country": "Belgium"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels #2", 
                        "country": "Belgium"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mainz", 
                        "country": "Germany"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest #1", 
                        "country": "Hungary"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest #2", 
                        "country": "Hungary"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy"
                    }, 
                    "name": "Morphosys"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novara", 
                        "country": "Italy"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chorz\u00f3w", 
                        "country": "Poland"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krak\u00f3w", 
                        "country": "Poland"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "L\u00f3dz", 
                        "country": "Poland"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Slupsk", 
                        "country": "Poland"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid #1", 
                        "country": "Spain"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid #2", 
                        "country": "Spain"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid #3", 
                        "country": "Spain"
                    }, 
                    "name": "MorphoSys Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Morphosys Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Germany", 
                "Hungary", 
                "Italy", 
                "Poland", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIa, Open-label, Multicenter Study of Single-Agent MOR00208, an Fc-optimized Anti-CD19 Antibody in Patients With Relapsed or Refractory Non-Hodgkin\u00b4s Lymphoma (NHL)", 
        "overall_contact": {
            "email": "info@morphosys.com", 
            "last_name": "Roman Korolkiewicz", 
            "phone": "+49 89 89927", 
            "phone_ext": "0"
        }, 
        "overall_official": {
            "affiliation": "Ohio State University", 
            "last_name": "Kristi Blum, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Paul-Ehrlich-Institut", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Spanish Agency of Medicines", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Hungary: National Institute of Pharmacy", 
                "Belgium: Federal Agency for Medicinal Products and Health Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ORR=CR (Complete Remission) + PR(Partial Remission)\nAntitumor activity of MOR00208", 
            "measure": "Overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685008"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "1. Patients response duration evaluation by hematology, bone marrow aspirated or biopsy, CT", 
                "safety_issue": "No", 
                "time_frame": "bi monthly, up to  48 months"
            }, 
            {
                "measure": "2. Safety will be evaluated by assessing adverse events, clinical lab data and vital signs, ECG, physical exam", 
                "safety_issue": "Yes", 
                "time_frame": "weekly, up to 4 years"
            }, 
            {
                "measure": "3. Pharmacokinetics of MOR00208 (Pharmacokinetic assessment comprises: Cmax, tmax, t1/2, CL", 
                "safety_issue": "No", 
                "time_frame": "weekly, up to 12 weeks; 0, 1, 4, 24 hours post dose"
            }, 
            {
                "measure": "4. Number of patients who develop anti-MOR00208 antibodies as a measure of immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "monthly up to 4 years"
            }
        ], 
        "source": "MorphoSys AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MorphoSys AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}